Use of imatinib mesylate in patients with CML in chronic phase resistant to interferon-alfa: Factors defined at start of therapy that predict disease progression and survival

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Author(s): Marin D, Marktel S, O'Brien SG, Olavarria E, Apperley J, Goldman J

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: 44th Annual Meeting of the American Society of Hematology

Year of Conference: 2002

Pages: 326B-326B

Publisher: Blood: American Society of Hematology

Notes: Abstract 4853

Library holdings: Search Newcastle University Library for this item

ISBN:

ePrints